Skip to main content

Tides of inflammation: impact of biologics.

Publication ,  Journal Article
St Clair, EW
Published in: J Rheumatol Suppl
September 2002

Increased knowledge about the mechanisms of joint inflammation and damage has profoundly shaped the development of new therapies for rheumatoid arthritis (RA). The first stop on this remarkable bench-to-bedside journey has been the biologics targeting tumor necrosis factor-alpha (TNF-alpha) and interleukin 1 (IL-1). These engineered adaptations of naturally occurring molecules function to neutralize the biological activity of proinflammatory cytokines overproduced in the joints of patients with RA. The successful translation of this approach into the clinic has had a substantial effect on the care of patients with RA.

Duke Scholars

Published In

J Rheumatol Suppl

ISSN

0380-0903

Publication Date

September 2002

Volume

65

Start / End Page

22 / 26

Location

Canada

Related Subject Headings

  • Treatment Outcome
  • Sialoglycoproteins
  • Severity of Illness Index
  • Receptors, Tumor Necrosis Factor
  • Range of Motion, Articular
  • Pain Measurement
  • Male
  • Interleukin 1 Receptor Antagonist Protein
  • Infliximab
  • Immunoglobulin G
 

Citation

APA
Chicago
ICMJE
MLA
NLM
St Clair, E. W. (2002). Tides of inflammation: impact of biologics. J Rheumatol Suppl, 65, 22–26.
St Clair, E William. “Tides of inflammation: impact of biologics.J Rheumatol Suppl 65 (September 2002): 22–26.
St Clair EW. Tides of inflammation: impact of biologics. J Rheumatol Suppl. 2002 Sep;65:22–6.
St Clair, E. William. “Tides of inflammation: impact of biologics.J Rheumatol Suppl, vol. 65, Sept. 2002, pp. 22–26.
St Clair EW. Tides of inflammation: impact of biologics. J Rheumatol Suppl. 2002 Sep;65:22–26.

Published In

J Rheumatol Suppl

ISSN

0380-0903

Publication Date

September 2002

Volume

65

Start / End Page

22 / 26

Location

Canada

Related Subject Headings

  • Treatment Outcome
  • Sialoglycoproteins
  • Severity of Illness Index
  • Receptors, Tumor Necrosis Factor
  • Range of Motion, Articular
  • Pain Measurement
  • Male
  • Interleukin 1 Receptor Antagonist Protein
  • Infliximab
  • Immunoglobulin G